Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease (scientific article)

Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system

Q28484499

FGF21 requires βklotho to act in vivo

Q28485347

Fundamentals of FGF19 & FGF21 action in vitro and in vivo

Q28729024

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

Q29614930

Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis

Q30448524

The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance.

Q34094150

Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes.

Q34300009

Fibroblast growth factor 21 corrects obesity in mice

Q34805555

Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk

Q35171570

Nrf2 represses FGF21 during long-term high-fat diet-induced obesity in mice

Q35227185

The Klotho gene family as a regulator of endocrine fibroblast growth factors

Q37343638

FGFs and metabolism

Q37580556

Pediatric nonalcoholic fatty liver disease in 2009.

Q37601653

Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease

Q37781747

Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment

Q37847587

Regulation of ion channels by secreted Klotho

Q37991260

Circulating fibroblast growth factors as metabolic regulators--a critical appraisal

Q38065349

TNF-α represses β-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway

Q39317227

Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.

Q39374896

Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice

Q43224118

Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis

Q43577294

Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis

Q46792569

Italian cross-sectional growth charts for height, weight and BMI (6-20 y).

Q47192450

Restoration of klotho expression induces apoptosis and autophagy in hepatocellular carcinoma cells.

Q54279104

Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease

Q57116843

Nonalcoholic fatty liver disease in children

Q62066966

Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine

Q63609769

Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome

Q82939022

Pathology of nonalcoholic fatty liver disease

Q83094715

Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee

Q83583931

Fibroblast growth factor 21 as a biomarker for NAFLD: Integrating pathobiology into clinical practice

Q84962979

P275

Creative Commons Attribution 4.0 International

copyrighted

issue

language of work or name

English

Q1860

P921

main subject

metabolic dysfunction–associated steatotic liver disease

Q1546498

P304

page(s)

e67160

P577

publication date

2013-06-26

P1433

published in

PLOS One

Q564954

P1476

title

Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease

P478

volume

Reverse relations

cites work (P2860)

Q58694534	A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents
Q59813695	Bidirectional Association between Nonalcoholic Fatty Liver Disease and Gallstone Disease: A Cohort Study
Q91657985	Bile Acid Diarrhea and NAFLD: Shared Pathways for Distinct Phenotypes
Q36023779	Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease
Q30410638	Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population
Q57111531	Developmental regulation of the gut-liver (FGF19-CYP7A1) axis in neonates
Q37689828	Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Q93165621	Effect of circulating exosomes derived from normal-weight and obese women on gluconeogenesis, glycogenesis, lipogenesis and secretion of FGF21 and fetuin A in HepG2 cells
Q51265948	Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial.
Q26781556	Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy
Q52699090	Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice.
Q36061647	Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets
Q37137238	Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice.
Q33652164	Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.
Q47368100	Friends Turned Foes: Angiogenic Growth Factors beyond Angiogenesis
Q48024919	Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD.
Q28118967	Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis
Q51742682	NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Q60922497	NGM282: a step forward in the nonalcoholic steatohepatitis treatment landscape?
Q44741522	Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in obese adolescents: a looming marker of cardiac dysfunction
Q58705640	Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
Q33831717	Pediatric Non-Alcoholic Fatty Liver Disease
Q38665591	Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines
Q28076863	Regulation of Hepatic Stellate Cells and Fibrogenesis by Fibroblast Growth Factors
Q35836340	Regulation of bile acid homeostasis by the intestinal Diet1-FGF15/19 axis
Q55491642	Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial.
Q57294546	Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications
Q92025196	Serum FGF21 Levels in Obese Korean Children and Adolescents
Q37605923	Serum fibroblast growth factor 19 is decreased in patients with overt hypothyroidism and subclinical hypothyroidism
Q92697803	Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps
Q38303270	Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target.
Q90737854	Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH)
Q38235454	The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target

P819	ADS bibcode	2013PLoSO...867160A
P356	DOI	10.1371/JOURNAL.PONE.0067160
P932	PMC publication ID	3694051
P698	PubMed publication ID	23840612
P5875	ResearchGate publication ID	248385777